NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer.
Several members of the department hold leadership positions, including Dr. Waggoner who is a member of several committees, and Nancy Fusco, RN who is Chairperson of the Protocol Working Group Mentorship Committee.
Clinical Trials
| Trial # | Trial Type | Trial Information |
|---|---|---|
| GOG 0229O | Endometrial Recurrent or Persistent | A Randomized Phase II Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK 241795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer |
| GOG 0238 | Uterine Corpus | A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus |
| GOG 0170R | Ovary, Peritoneal, Recurrent/Persistent | A Phase II Evaluation of Dalantercept (NSC #757172, IND #116598), A Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
| GOG 0186H | Ovary, Peritoneal, Recurrent/Persistent | A Randomized Phase II Evaluation of Weekly Paclitaxel Versus Weekly Paclitaxel with Oncolytic Reovirus(REOLYSIN® NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| CASE 4812 | Cervix | Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed with Stage IB-IVA Cervical Cancer and Stage II-IVA Vaginal Cancer |
| GOG 0264 | Ovary, Sex Cord Stromal Tumor | A Randomized Phase II Trial Of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex-Cord Stromal Tumors |
| GOG 0277 | Leiomyosarcoma | A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) followed by Doxorubicin (NSC# 123127) v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma |
| GOG 0279 | Vulva | A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC # 613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva |
| GOG 0244 | Non-Cancer Treatment and Surgical Studies | The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients |
| CASE 9812 | Non-Cancer Treatment and Surgical Studies | Acquisition of Human Gynecologic Cancer Specimens and Serum to Study the Causes, Diagnosis, Prevention, and Treatment of Gynecologic Cancers |
| GOG 0225 | Non-Cancer Treatment and Surgical Studies | Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? |
| CARI 1Z12 | Non-Cancer Treatment and Surgical Studies | A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer |
| CASE 5811 | Non-Cancer Treatment and Surgical Studies | REWARD (Revving-Up Exercise for Sustained Weight Loss by Altering Neurological Reward and Drive): A Randomized Trial of Assisted Exercise in Obese Endometrial Cancer Patient |
| GOG 0278 | Non-Cancer Treatment and Surgical Studies | Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 |
| CASE 13813 | Non-Cancer Treatment and Surgical Studies | Referral of Obese Endometrial Cancer Survivors to a Bariatric Specialist and a Healthier Survivorship: A Prospective Intervention Cohort |
| CASE 13813 | RTOG Trials | Referral of Obese Endometrial Cancer Survivors to a Bariatric Specialist and a Healthier Survivorship: A Prospective Intervention Cohort |
Contact
- Director: Steven E. Waggoner, MD